An investigational obesity therapy from Boehringer Ingelheim has delivered up to 16.6% average weight loss in phase 3, marking a positive result in a competitive market.
The company is chasing established players like Novo Nordisk and Eli Lilly with a molecule that takes a slightly different approach to fat reduction.
The drug survodutide works by reducing appetite while also targeting metabolism in the liver. This includes reducing fat in liver cells, regulating metabolic function and potentially improving inflammation and fibrosis.
Study results
The results come from the SYNCHRONIZE-1 trial, in which adults were treated with the drug over 76 weeks.
Most participants responded well to treatment, with 85.1% achieving at least 5% weight loss compared with 38.8% in the placebo group. Participants lost up to 17.8 kg on average, alongside significant reductions in waist circumference.
Early analysis suggests the weight loss was driven largely by reductions in fat mass, with a relatively small contribution from lean tissue. This may be clinically relevant, as weight loss with existing therapies can lead to unwanted muscle loss in some patients.
In line with other GLP-1 based therapies, participants in the trial experienced gastrointestinal events, with discontinuations happening more frequently during the dose escalation phase.
Commenting on the findings, Carel le Roux, Professor, University College Dublin and global coordinating investigator of the trial, said: “There is an urgent need for new therapies that go beyond weight reduction alone to support meaningful improvements in metabolic health.
“Survodutide’s dual agonism is particularly exciting, as it offers a promising approach to addressing this significant unmet need in care.”
What comes next
Boehringer will continue to evaluate survodutide in other phase 3 trials, including in people with type 2 diabetes and metabolic dysfunction-associated steatohepatitis.
Further data from this trial are expected in 2026, with full results due to be presented at the American Diabetes Association Scientific Sessions 2026 in June.
Featured image: Prostock-studio on Adobe Stock
